XNCR Xencor, Inc.

36.911.43 (+4.03%)
Close: September 20, 2019

Quote

Previous Close
$36.91
Day Range
$35.25-$37.44
52 Week Range
$27.75-$46.33
Volume
1,471,665
Avg Volume
350,875
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$2.09B
Enterprise Value (EV)
$1.80B
PE Ratio
42.42
EV/EBITDA
-23.68
Price/Sales
-
Price/Book
4.01
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$75.92M
EPS, ttm
$0.87
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/11/2019 (50 days)
Debt to Equity
-
Debt
-
Cash
$292.06M
Net Debt
-

Performance

Beta
1.43
200 Day Moving Avg
$35.44
50 Day Moving Avg
$39.88
52 Week Change
-13.94%
YTD Change
7.16%
1 Month Change
-10.63%
3 Month Change
4.98%
6 Month Change
14.98%
1 Year Change
-13.94%
2 Year Change
39.37%
5 Year Change
278.65%

Share Count

Shares Outstanding
56.6M
Float
56.1M
Restricted Shares
503.5K
Restricted Shares, %
0.89%

Xencor, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Bassil I. Dahiyat

Website: http://www.xencor.com

Description: Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Employees: 156